Lys58
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys58  -  ARNT (human)

Site Information
DDGEGNSkFLRCDDD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15293521
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
leukemia ( 3 , 4 ) , chronic myelogenous leukemia ( 3 , 4 ) , non-small cell lung cancer ( 1 , 2 ) , non-small cell squamous cell lung carcinoma ( 2 )
Relevant cell line - cell type - tissue:

References 

1

Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info